Invion Limited (ASX:IVX)

Market Cap	4.15M -51.5%
Revenue (ttm)	384.71K
Net Income	-5.63M
EPS	-0.06
Shares Out	109.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,877
Open	0.0420
Previous Close	0.0400
Day's Range	0.0380 - 0.0420
52-Week Range	0.0320 - 0.1100
Beta	0.42
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 25, 2026

About Invion

Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IVX

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error